The European Commission (EC) has awarded a grant to Latima to commercialise its cancer virotherapy medicine in the European Union (EU) markets.

The commercialisation grant has been awarded by Latima within a framework of Horizon 2020 programme, ‘Dedicated support to the biotechnology SMEs closing the gap from lab to market’.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Cancer virotherapy is a treatment of cancer that uses a virus to find and destroy malignant cells in the patient’s body.

Also known as oncolytic virotherapy, this type of cancer treatment is evidence-based and recognised as safe and effective therapy to treat cancer patients.

Being the biggest EU Research and Innovation programme, the Horizon 2020 receives approximately €80bn of funding over seven years, from 2014 to 2020.

See Also:

The Horizon 2020 programme takes new discoveries from the laboratory to the market, is administered by the European Commission in Brussels and can be used by participants from across the EU.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Latima is part of Rigvir that develops and promotes cancer virotherapy worldwide.

Rigvir finance director Karlis Urbans said: “There are millions of cancer patients around the world in need of this unique cancer medicine.

"There are millions of cancer patients around the world in need of this unique cancer medicine."

“At the moment Rigvir is approved in three countries so far, however other patients can get virotherapy with Rigvir via medical tourism.

“I hope that this grant will make cancer virotherapy more available for everyone who would benefit from it. Cancer patients deserve this safe, effective and humane cancer treatment.”

Latima is the producer of the world’s first approved cancer virotherapy medicine.

In 2004, the first cancer virotherapy medicine was approved for melanoma treatment by the State Agency of Medicines of Latvia, an EU member state.

Image: First oncolytic virotherapy. Photo: courtesy of PRNewsFoto / Latima.